Condition

Deep Vein Thrombosis

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 25 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials25

Recruiting1

Common interventions21

Lead sponsors shown15

Clinical trials

25 shown

Apixaban in ThrombocytopeniaNCT06886516 · 2025-02-28

Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer SurgeryNCT06451003 · 2024-07-01

ACTIVE_NOT_RECRUITING

Primary Care-Hospital Embedding: a Prospective, Multicentric, Observational StudyNCT05723185 · 2023-02-13

ACTIVE_NOT_RECRUITING

Machine Learning-based Models in Prediction of DVT and PTE in AECOPD PatientsNCT05905874 · 2023-01-01

Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and WalesNCT04838106 · 2020-08-01

Improving Safety of Diagnosis and Therapy in the Inpatient SettingNCT04393909 · 2019-07-01

The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort StudyNCT03835780 · 2019-02-01

Prevention and Prophylaxis of Cancer Associated Thrombosis in High Risk Oncology PatientsNCT03909399 · 2019-01-25

Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys StudyNCT03650127 · 2018-02-02

Long-term Outcome After Heparin and Edoxaban Versus Heparin Plus Vit K Antagonists for Acute DVT and PENCT03757481 · 2018-01-01

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous ThromboembolismNCT03240120 · 2017-09-01

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation TherapyNCT03080883 · 2017-07-14

A Survey of Hospitalizations in Cardiology Units in Sub-Saharan AfricaNCT03231449 · 2017-02-01

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous ThromboembolismNCT02585713 · 2015-11-20

Venous Thromboembolic Complications in Ovarian CancerNCT02480790 · 2014-11-01

Correlation Between Reticulated Platelets and Major Adverse Cardiac and Cerebrovascular Events After Noncardiac SurgeryNCT02097602 · 2014-02-01

Anticoagulation Length in Cancer Associated ThrombosisNCT01817257 · 2013-12-01

Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes SurveysNCT02032030 · 2012-07-01

Study on Thrombosis Therapy in German Cancer PatientsNCT01559883 · 2012-02-01

Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon CancerNCT00967148 · 2009-06-01

Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 InducerNCT00786422 · 2009-05-01

Screening for Occult Malignancy in Patients With Idiopathic Venous ThromboembolismNCT00773448 · 2008-09-01

3 Screen Electronic AlertNCT00550082 · 2007-07-01

Epidemiology of Venous ThromboembolismNCT00456196 · 2006-04-01

Multi-Center Human Alert Trial to Prevent DVT and PENCT00409136 · 2006-03-01

Common interventions

Leading sponsors

Brigham and Women's Hospital 4 Academic and Community Cancer Research United 2 Ottawa Hospital Research Institute 2 Bayer 1 Cardiff University 1 Cardiologie et Développement 1 Hellenic Society of Medical Oncology 1 LEO Pharma 1 Markus Perola 1 Medical University of South Carolina 1 Momentum Data 1 Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery 1 Rovere Querini Patrizia 1 Rushad Patell 1 Technical University of Munich 1

Trial status mix

COMPLETED14

UNKNOWN7

ACTIVE_NOT_RECRUITING2

RECRUITING1

TERMINATED1

Phase mix

NA5

PHASE33

PHASE22

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.